Novel oxadiazole derivatives as sphingosine 1-phosphate (s1p) receptor modulators

Abstract

The present invention relates to novel oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

What is claimed is: 
     
         1 . A method of treating an immunosuppressant disorder associated with the sphingosine-1-phosphate receptor modulation, wherein the immunosuppressant disorder is selected from: rheumatoid arthritis, psoriasis, atherosclerosis, autoimmune uveitis, dry eye, inflammatory bowel diseases, atopic allergy, atopic dermatitis, contact dermatitis, multiple sclerosis, Sjogren's syndrome and organ transplant rejection, in a mammal in need thereof, which comprises administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of at least one compound represented by Formula I or a pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
         wherein: 
       
       
         
           
           
               
               
           
         
       
       is 
       
         
           
           
               
               
           
         
       
       is 
       
         
           
           
               
               
           
         
         R 1  is H, halogen, —OC 1-8  alkyl, C 1-8  alkyl, CN, C(O)R 11 , NR 12 R 13  or hydroxyl; 
         R 2  is H, halogen, —OC 1-8  alkyl, C 1-8  alkyl, CN, C(O)R 11 , NR 12 R 13  or hydroxyl; 
         R 3  is H, halogen, —OC 1-8  alkyl, C 1-8  alkyl, CN, C(O)R 11 , NR 12 R 13  or hydroxyl; 
         R 4  is H, halogen, —OC 1-8  alkyl, C 1-8  alkyl, CN, C(O)R 11 , NR 12 R 13  or hydroxyl; 
         R 5  is H, halogen, —OC 1-8  alkyl, C 1-8  alkyl, CN, C(O)R 11 , NR 12 R 13  or hydroxyl; 
         R 6  is H, halogen, —OC 1-8  alkyl, C 1-8  alkyl, CN, C(O)R 11 , NR 12 R 13  or hydroxyl; 
         R 7  is H, halogen, —OC 1-8  alkyl, C 1-8  alkyl, CN, C(O)R 11 , NR 12 R 13  or hydroxyl; 
         R 8  is H, halogen, —OC 1-8  alkyl, C 1-8  alkyl, CN, C(O)R 11 , NR 12 R 13  or hydroxyl; 
         L is O, S or NH; 
         R 11  is H or C 1-8  alkyl; 
         R 12  is H or C 1-8  alkyl; 
         R 13  is H or C 1-8  alkyl; 
         R 14  is H, C 1-6  alkyl or C 3-6  cycloalkyl; and 
         R 15  is H, C 1-6  alkyl or C 3-6  cycloalkyl. 
       
     
     
         2 . The method according to  claim 1 , wherein said compound is represented by Formula I wherein:
 L is S.   
     
     
         3 . The method according to  claim 1 , wherein said compound is represented by Formula I wherein:
 L is O.   
     
     
         4 . The method according to  claim 1 , wherein said compound is represented by Formula I wherein:
 L is NH.   
     
     
         5 . The method according to  claim 1 , wherein said compound is represented by Formula I wherein: 
       
         
           
           
               
               
           
         
       
       is 
       
         
           
           
               
               
           
         
       
       is 
       
         
           
           
               
               
           
         
       
     
     
         6 . The method according to  claim 1 , wherein said compound is represented by Formula I wherein: 
       
         
           
           
               
               
           
         
       
       is 
       
         
           
           
               
               
           
         
       
       is 
       
         
           
           
               
               
           
         
         L is O, S or NH; 
         R′ is H, halogen or C 1-6  alkyl; 
         R 2  is H, halogen or C 1-6  alkyl; 
         R 3  is H, halogen or C 1-6  alkyl; 
         R 4  is H, halogen, —OC 1-6  alkyl or C 1-6  alkyl; 
         R 5  is H, halogen, —OC 1-6  alkyl or C 1-6  alkyl; 
         R 6  H, halogen, —OC 1-6  alkyl or C 1-6  alkyl; 
         R 7  is H, halogen or C 1-6  alkyl; 
         R 8  is H, halogen or —C 1-6  alkyl; 
         R 14  is H, C 1-6  alkyl or C 3-6  cycloalkyl; and 
         R 15  is H, C 1-6  alkyl or C 3-6  cycloalkyl. 
       
     
     
         7 . The method according to  claim 6 , wherein said compound is represented by Formula I wherein:
 L is NH.   
     
     
         8 . The method according to  claim 6 , wherein said compound is represented by Formula I wherein:
 L is S.   
     
     
         9 . The method according to  claim 6 , wherein said compound is represented by Formula I wherein:
 L is O.   
     
     
         10 . The method according to  claim 1 , wherein the mammal is a human. 
     
     
         11 . The method according to  claim 1 , wherein the pharmaceutical composition further comprises pharmaceutically acceptable adjuvants, diluents or carriers. 
     
     
         12 . The method according to  claim 1 , wherein the compound represented by Formula I is selected from:
 3-(5-(((3,4-dimethylphenyl)amino)(phenyl)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((3-chlorophenyl)((3,4-dimethylphenyl)amino)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((2-chlorophenyl)((3,4-dimethylphenyl)thio)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((3,4-dichlorophenoxy)(phenyl)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((3-chlorophenyl)((2-methylfuran-3-yl)thio)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((4-bromophenoxy)(4-chlorophenyl)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((4-chlorophenyl)(3,4-dimethylphenoxy)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((3-bromophenyl)((3,4-dimethylphenyl)thio)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-(((3,4-dimethylphenyl)thio)(3-fluorophenyl)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((4-chlorophenyl)((2,4-dimethylphenyl)thio)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((4-chlorophenyl)(cyclohexylthio)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((4-chlorophenyl)(p-tolylthio)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-(((4-isopropylphenyl)thio)(phenyl)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((4-chlorophenyl)((4-methoxyphenyl)thio)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((4-chloro-3-methylphenoxy)(4-chlorophenyl)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((4-chlorophenyl)((3,4-dimethylphenyl)thio)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((4-chlorophenoxy)(4-chlorophenyl)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((4-chlorophenoxy)(phenyl)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((3,4-dichlorophenyl)((3,4-dimethylphenyl)thio)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((3-chlorophenyl)((3,4-dimethylphenyl)thio)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((3-chlorophenoxy)(4-chlorophenyl)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((cyclohexylthio)(3-(trifluoromethyl)phenyl)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((4-chlorophenyl)(p-tolyloxy)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   N-methyl-3-(5-(phenyl(phenylthio)methyl)-1,2,4-oxadiazol-3-yl)pyridin-2-amine;   3-(5-((4-isopropylphenoxy)(phenyl)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((2,3-dichlorophenoxy)(phenyl)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((2-chlorophenyl)(p-tolyloxy)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((3-chlorophenyl)(cyclohexyloxy)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((3-chlorophenyl)(p-tolyloxy)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((4-chlorophenoxy)(3-chlorophenyl)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((4-chlorophenoxy)(2-chlorophenyl)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((2-chlorophenyl)(m-tolyloxy)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((3-chlorophenoxy)(2-chlorophenyl)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((2-chlorophenyl)(3-isopropylphenoxy)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((2-chlorophenyl)(3,4-dimethylphenoxy)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((3-chlorophenyl)(3,4-dimethylphenoxy)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;   3-(5-((3-chlorophenyl)(m-tolyloxy)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine; and   3-(5-((3,4-dimethylphenoxy)(phenyl)methyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine.